Zealand Pharma A/S. logo

ZEAL

Zealand Pharma A/S.

$17.59

Earnings Summary

Revenue
$221.02Mn
Net Profits
$-58.18Mn
Net Profit Margins
-26.32%

Highlights

Revenue:

Zealand Pharma A/S.’s revenue jumped 1009.63% since last year same period to $221.02Mn in the Q2 2020. On a quarterly growth basis, Zealand Pharma A/S. has generated 1679.95% jump in its revenue since last 3-months.

Net Profits:

Zealand Pharma A/S.’s net profit jumped 57.57% since last year same period to $-58.18Mn in the Q2 2020. On a quarterly growth basis, Zealand Pharma A/S. has generated 67.59% jump in its net profits since last 3-months.

Net Profit Margins:

Zealand Pharma A/S.’s net profit margin jumped 96.18% since last year same period to -26.32% in the Q2 2020. On a quarterly growth basis, Zealand Pharma A/S. has generated 98.18% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Zealand Pharma A/S. post its latest quarter earnings

EPS Estimate Current Quarter
-6.61
EPS Estimate Current Year
-6.61

Highlights

EPS Estimate Current Quarter:

Zealand Pharma A/S.’s earning per share (EPS) estimates for the current quarter stand at -6.61 - a -3.44% fall from last quarter’s estimates.

EPS Estimate Current Year:

Zealand Pharma A/S.’s earning per share (EPS) estimates for the current year stand at -6.61.

Key Ratios

Key ratios of the Zealand Pharma A/S. post its Q1 2022 earnings

Earning Per Share (EPS)
-5.16
Return on Assets (ROA)
-0.34
Return on Equity (ROE)
-0.94

Highlights

Earning Per Share (EPS):

Zealand Pharma A/S.’s earning per share (EPS) jumped 10.73% since last year same period to -5.16 in the Q1 2022. This indicates that the Zealand Pharma A/S. has generated 10.73% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Zealand Pharma A/S.’s return on assets (ROA) stands at -0.34.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Zealand Pharma A/S.’s return on equity (ROE) stands at -0.94.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-6.61
-5.16
21.94%

Company Information

Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The head office is situated in Søborg near Copenhagen

Organisation
Zealand Pharma A/S.
Industry
Manufacturing
CEO
Emmanuel Dulac

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*